Subscriber access provided by UB + Fachbibliothek Chemie | (FU-Bibliothekssystem)
Article
A systematic study of molecular interactions of anionic drugs with a dimethylaminoethyl methacrylate copolymer regarding solubility enhancement Wiebke Saal, Alfred Ross, Nicole Wyttenbach, Jochem Alsenz, and Martin Kuentz Mol. Pharmaceutics, Just Accepted Manuscript • DOI: 10.1021/acs.molpharmaceut.6b01116 • Publication Date (Web): 13 Mar 2017 Downloaded from http://pubs.acs.org on March 19, 2017
Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.
Molecular Pharmaceutics is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.
Page 1 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
1
A systematic study of molecular interactions of anionic drugs with
2
a
3
solubility enhancement
dimethylaminoethyl
methacrylate
copolymer
regarding
4 5
Wiebke Saal1,2, Alfred Ross3, Nicole Wyttenbach3, Jochem Alsenz3, Martin Kuentz1*
6
7
1
8
Technology, Gründenstrasse 40, 4132 Muttenz, Switzerland
9
2
University of Applied Sciences and Arts Northwestern Switzerland, Institute of Pharma
University of Basel, Institute of Pharmaceutical Technology, Klingelbergstrasse 50, 4056
10
Basel, Switzerland
11
3
12
Center Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
Roche Pharmaceutical Research & Early Development, Pre-Clinical CMC, Roche Innovation
13 14
Prof. Dr. Martin Kuentz
15
University of Applied Sciences and Arts Northwestern Switzerland
16
Institute of Pharma Technology
17
Gründenstrasse 40
18
4132 Muttenz / Switzerland
19
T +41 (61) - 467 46 88 / F +41 (61) - 467 47 01
20
[email protected] 21 22 23
1 ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
24
Page 2 of 32
For Table of Contents Use Only
25 26
A systematic study of molecular interactions of anionic drugs with a
27
dimethylaminoethyl
28
enhancement
methacrylate
copolymer
regarding
solubility
29 30
Wiebke Saal1,2, Alfred Ross3, Nicole Wyttenbach3, Jochem Alsenz3, Martin Kuentz1*
31
1
32
Gründenstrasse 40, 4132 Muttenz, Switzerland
33
2
34
Switzerland
35
3
36
Basel, F. Hoffmann-La Roche Ltd, Grenzacherstrasse 124, 4070 Basel, Switzerland
University of Applied Sciences and Arts Northwestern Switzerland, Institute of Pharma Technology,
University of Basel, Institute of Pharmaceutical Technology, Klingelbergstrasse 50, 4056 Basel,
Roche Pharmaceutical Research & Early Development, Pre-Clinical CMC, Roche Innovation Center
37
38
2 ACS Paragon Plus Environment
Page 3 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
39
Abstract
40
The methacrylate-copolymer Eudragit® EPO (EPO) has raised interest in solubility
41
enhancement of anionic drugs. Effects on aqueous drug solubility at rather low polymer
42
concentrations are barely known despite of their importance upon dissolution and dilution of
43
oral dosage forms. We provide evidence for substantial enhancement (factor 4-230) of
44
aqueous solubility of poorly water-soluble anionic drugs induced by low (0.1-5% (w/w))
45
concentration of EPO for a panel of seven acidic crystalline drugs. Diffusion data (determined
46
by 1H nuclear magnetic resonance spectroscopy) indicate that the solubility increasing effect
47
monitored by quantitative ultra-pressure liquid chromatography was caused primarily by
48
molecular API polymer interactions in the bulk liquid phase. Residual solid API remained
49
unaltered as tested by X-ray powder diffraction. The solubility enhancement (SE) revealed a
50
significant rank correlation (rSpearman= -0.83) with rDiffAPI, where SE and rDiffAPI are defined
51
ratios of solubility and diffusion coefficient in the presence and absence of EPO. SE
52
decreased in the order of indomethacin, mefenamic acid, warfarin, piroxicam, furosemide,
53
bezafibrate, and tolbutamide. The solubilizing effect was attributed to both ionic and
54
hydrophobic interactions between drugs and EPO. The excellent solubilizing properties of
55
EPO are highly promising for pharmaceutical development and the dataset provides first steps
56
towards an understanding of drug-excipient interaction mechanisms.
57
Keywords:
58
acidic drugs, solubility enhancement.
Nuclear magnetic resonance (NMR) spectroscopy, polymer-drug interaction,
59
3 ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
60
Introduction
61
An increasing number of new active pharmaceutical compounds (APIs) exhibit low water
62
solubility which may lead to poor oral bioavailability.1 Various approaches have been
63
reported to increase drug solubility for these candidates. Formulations were designed to
64
promote intestinal solubility like micro- and nanosuspensions,2 cyclodextrin complexes,3-5 and
65
lipid-based formulations.6, 7 Formulations can also target primarily a transient increase of bulk
66
concentrations by drug supersaturation, which thereby enhances absorptive flux.
67
Supersaturated states can be obtained in vivo by pH change when the dissolved compound is
68
transported from the acid stomach into the small intestine or by a loss of solubilization
69
capacity of a formulation as upon dilution, dispersion or digestion in the gastrointestinal
70
tract.8 Supersaturation is only beneficial if drug crystallization is slower than drug
71
absorption.9 The most common supersaturating formulations are amorphous solid dispersions
72
that are used to enhance the bioavailability of compounds belonging to biopharmaceutical
73
classification system (BCS) class II or IV.8, 10
74
This work focusses on the copolymer EPO that belongs to the family of methacrylic acid
75
copolymers. EPO is composed of dimethylaminoethyl methacrylate, butyl methacrylate, and
76
methyl methacrylate at molar ratios of 2:1:1 and is positively charged at physiological pH in
77
aqueous media. Figure 1 displays the molecular structure of this copolymer. EPO has been
78
widely used as pharmaceutical excipient for taste masking, moisture protection, enteric film-
79
coating, and sustained release drug delivery.11
4 ACS Paragon Plus Environment
Page 4 of 32
Page 5 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
80 81
Figure 1. Molecular structure of Eudragit® EPO.
82
EPO was more recently used to prepare solid dispersions, especially with anionic drugs12-14,
83
and outstanding results were obtained in terms of solubility and bioavailability
84
enhancement.12 Priemel et al. also reported in situ amorphization with EPO and
85
indomethacin15 and recently in situ amorphization with naproxen and ibuprofen was
86
evidenced.16
87
Different studies attempted to gain insights into the molecular interactions of the copolymer
88
EPO with anionic drugs. Kojima et al. and Higashi et al. used for example nuclear magnetic
89
resonance (NMR) spectroscopy to better understand the molecular basis of solubility
90
enhancement (SE) of solid dispersions and of supersaturated solutions using EPO and
91
mefenamic acid.12,
92
carrier in solid dispersions but also affects drug solubilization and supersaturation of acidic
93
drugs. Formulations with EPO therefore seem to become a research field in its own right.
94
However so far, only few compounds, exclusively in amorphous state, were studied.
95
Moreover, data for rather low polymer concentrations are rare, for example concentrations
96
that would result from dilution of oral dosage forms in the gastrointestinal tract. Another
97
aspect is that combinations of EPO and acidic drugs were primarily studied in the context of
13
These important pioneer studies showed that EPO acts not only as a
5 ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
12
98
solid dispersions.
The molecular interactions of the polymer and acidic drugs seem to be
99
also promising for other formulation types but such data are currently lacking.
100
We therefore studied the influence of EPO in solution on the solubility and solid state of
101
seven poorly water-soluble, acidic, chemically diverse drugs. Our final aim was to better
102
mechanistically understand how the molecular interactions of acidic drugs and EPO would
103
result in specific SE.
104
105
Experimental Section
106
Materials
107
Indomethacin (IMC), mefenamic acid (MFA), tolbutamide (TLB) and warfarin (WFN) were
108
obtained from Sigma Aldrich (St. Louis, USA), while bezafibrate (BZF) and piroxicam (PRX)
109
were from TCI Europe N.V. (Zwijndrecht, Belgium). Furosemide (FRS) was purchased from
110
Molekula GmbH (München, Germany) and amino alkyl metacrylate copolymer E, Eudragit®
111
EPO, (EPO) was obtained from Evonik (Darmstadt, Germany). Chemical structures of all
112
model compounds are shown in Figure 2. Hydrochloric acid (0.1 M) and sodium hydroxide
113
solution (0.1 M) were supplied by Merck KGaA (Darmstadt, Germany).
114 6 ACS Paragon Plus Environment
Page 6 of 32
Page 7 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
115
Figure 2. Chemical structure of model drugs.
116
Table 1. List of model drugs and selected physicochemical properties.
Compound Bezafibrate (BZF) Furosemide (FRS) Indomethacin (IMC) Mefenamic acid (MFA) Piroxicam (PRX) Tolbutamide (TLB) Warfarin (WFN) 117 118
Mw [g/mol] 361.8 330.7 357.8 241.3 331.4 270.4 308.3
pKaa 3.2 3.5 4.5 4.2 2.3 5.1 5.0
LogDb (pH 6.0) 1.8 0.0 1.4 3.3 -0.4 1.4 2.2
a
Measured pKa-values via photometric titration. Values calculated by the Marvin program suite (V.16.5.30) (ChemAxon Ltd., USA).
b
119
120
Methods
121
Sample preparation
122
Polymer solutions were prepared by dissolving EPO (0.1%, 0.5%, 1%, 2%, 3%, 4%, 5%
123
(w/w)) in deionized water and adjusting the pH of the solutions to pH 6.0 with hydrochloric
124
acid or sodium hydroxide at 25°C. All solutions were visually inspected for absence of
125
residual particles.
126
127
Viscosity measurements
128
Apparent viscosity was measured with a cone-plate-rheometer (Physica MCR 301, Anton
129
Paar GmbH, Graz, Austria) by applying a shear rate of 1000 min-1 for 2 min.
130 131
Solubility and residual solid analysis
132
Solubility of compounds in EPO-solutions was determined using a slightly modified 96-well
133
SORESOS17 assay, which measures both equilibrium solubility and solid form of the residual 7 ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
134
solid. In brief, APIs were dispensed using the powder-picking-method18 in 96-well flat bottom
135
plates (Corning Inc., Durham, USA) and stirring bars and excipient vehicles (150 µL) were
136
added. The plate was then sealed with pre-slit silicon caps and the mixtures were agitated by
137
head-over-head rotation for 24 h, 48 h and one week at room temperature. After equilibration,
138
the suspensions were carefully transferred into 96-well filter plates and liquid was separated
139
from residual solid by centrifugation. Collected filtrates were diluted with N-methyl-2-
140
pyrrolidone and drug content was determined using a Waters Acquity Ultra Performance
141
Liquid Chromatographic (UPLC) system equipped with a 2996 Photodiode Array Detector
142
and an Acquity UPLC BEH C18 column (2.1x50 mm, 1.7 µm particle size) from Waters
143
(Milford, USA). Table 2 summarizes the experimental conditions (solvents, composition of
144
mobile phase, detection wave length) used for the drugs. An isocratic flow of a mixture of
145
solvent A and solvent B was applied for 0.3 min at a flow rate of 0.75 mL/min. Subsequently,
146
the concentration of solvent B was linearly increased to 100% within 0.5 min. Solid state
147
analysis of residual solid was performed by X-ray powder diffraction (XRPD) using a STOE
148
Stadi P Combi diffractometer with a primary Ge-monochromator (Cu Kα radiation), imaging
149
plate position sensitive detector (IP-PSD), and a 96-well sample stage. The IP-PSD allowed
150
simultaneous recording of the diffraction pattern on both sides of the primary beam which
151
were summed up by the software STOE WinXPOW to reduce effects related to poor crystal
152
orientation statistics. Samples were analyzed directly in the 96-well filter plate with an
153
exposure time of 5 min per well.
154 155
Table 2. Experimental conditions used for UPLC analysis. Compound
Composition a
Detection
(A:B) [%]
wavelength [nm]
BZF
50:50
254
FRS
75:25
274
IMC
50:50
318
8 ACS Paragon Plus Environment
Page 8 of 32
Page 9 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
156 157
Molecular Pharmaceutics
MFA
40:60
352
PRX
65:35
342
TLB
60:40
265
WFN
50:50
283
a
Mobile phase A: deionized water with 0.1% (v/v) triethylamine adjusted to pH 2.2 with methanesulfonic acid, mobile phase B: acetonitrile.
158 159
1
160
Solutions for NMR analyses were prepared by incubating APIs for 24 h in a 0.5% (w/w)
161
EPO-solution in deuterium oxide (D2O) at pH 6.0. Samples were then centrifuged and
162
supernatants (550 µl) were transferred to short disposable 5 mm NMR tubes.
163
All NMR measurements were performed with a Bruker 600 MHz Avance II spectrometer
164
equipped with a cryogenic QCI probe head at a temperature of 300 K. Spectrometer operation
165
and data processing was done by Topsin 2.1 software (Bruker, Fällanden, Switzerland). For
166
all samples matching/tuning of the probe head and the 90° pulse were determined fully
167
automated. Pseudo 2D 1H diffusion ordered spectroscopy with bipolar gradient pulse pairs
168
and 2 spoil gradients19 was measured for all samples with presaturation of residual water.
169
Data points (32k) were acquired over 18 ppm sweep-width. The interscan delay was set to 1.5
170
s and the SMSQ10.100 shaped bipolar gradient was ramped from 2.65 to 50.35 gauss/cm in
171
16 equidistant steps. A diffusion time of 300 ms was used. Spectra were processed with a lb =
172
1 exponential filtering.
173
Diffusion coefficient D was fitted by use of the T1/T2 relaxation module implemented within
174
the Topsin 2.1 (Bruker, Switzerland). For most molecules at least one API and excipient
175
related NMR signal was identified by visual inspection.
H NMR spectroscopy
176
177
Statistical analysis and molecular modeling 9 ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
178
The program STATGRAPHICS Centurion XVI ed. Professional (V. 16.1.15) from Statpoint
179
Technologies Inc. (Warrenton, USA) was used for statistical rank correlation (Spearman)
180
testing.
181
For graphical representation of the mefenamic acid interaction with EPO, both ionized
182
molecules were assigned to an AMBER force field using the software Chemsite (V.10.4.,
183
Norgwyn Montgomery Software Inc., Northwales, USA). The starting configuration was
184
based on docking the anionic model drug to positively charged nitrogen of the polymer that
185
was modeled as residue of 10 monomers. Following energy minimization, the molecular
186
dynamics simulation was running for 10 ns while using an implicit Born solvation model
187
(with a relative permittivity of 78.4) at a temperature of 300 K.
188
189
Results
190
Viscosity
191
The apparent viscosity was measured under shear (Table 3) for all solutions of EPO. A slight
192
increase in viscosity with polymer concentration was observed, however all solutions had a
193
rather low viscosity. These EPO-solutions were used to determine drug solubility after 24 and
194
48 h. Most drugs reached equilibrium solubility within 24 h, some compounds (MFA, FRS,
195
TLB) showed differences between the selected time points especially at higher polymer
196
concentration. For those compounds solubility was additionally determined after one week to
197
prove that equilibrium was reached. Finally, 48 h was selected as incubation time for all
198
solubility experiments (shown in Table 4 and Figures 3 and 4) because all systems have
199
reached equilibrium after this time.
200 201
Table 3. Apparent viscosity of EPO-solutions (25°C, 1000s-1).
10 ACS Paragon Plus Environment
Page 10 of 32
Page 11 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
Concentration of
Viscosity [mPas]
EPO [%, (w/w)]
(Standard deviation, n=3)
0.1
1.1 (0.01)
0.5
1.1 (0.01)
1.0
1.2 (0.01)
2.0
1.5 (0.02)
3.0
1.9 (0.05)
4.0
2.1 (0.01)
5.0
2.3 (0.00)
202 203
Solubility and residual solid analysis
204
All test solutions were adjusted to pH 6 and following equilibration, the residual solid was
205
analyzed by means of XRPD. Compared to water, all model compounds displayed an
206
enormous SE in the different EPO-solutions (Fig. 3-4 and Table 4) with SE factors of
207
approximately 4 - 230 fold.
208 209
Table 4. Drug solubility and pH in water after incubation for 48h.
Compound
Solubility in water
pH in water (standard
(standard deviation, n=3)
deviation, n=3)
[mg/ml] BZF
0.016 (0.003)
4.6 (0.1)
FRS
0.024 (0.007)
4.4 (0.0)
IMC
0.007 (0.003)
5.0 (0.2)
< 0.001
6.1 (0.1)
PRX
0.008 (0.001)
5.4 (0.1)
TLB
0.083 (0.007)
5.0 (0.1)
WFN
0.005 (0.001)
5.4 (0.2)
MFA*
210
*Aqueous solubility was below the limit of detection.
211 212
11 ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
213 214
Figure 3. Solubility of BZF, IMC, PRX, and WFN in EPO-solutions after 48 h equilibration
215
at room temperature.
216 217
BZF, IMC, PRX and WFN (Figure 3) reached maximum solubility at 2% EPO (w/w) and
218
their solubility increased with the polymer concentration. Above 2% EPO, solubility
219
decreased again and finally reached a kind of plateau. In contrast, FRS and MFA (Figure 4)
220
showed a constant increase of solubility with polymer concentration up to 5% EPO. TLB
221
(Figure 4) was the only tested compound that reached a kind of plateau at 2% EPO where the
222
solubility did not decrease at higher EPO concentrations.
223 224
The residual solid analysis confirmed that none of the tested compounds changed its
225
polymorphic form. Therefore, it is likely that the SE resulted from drug-EPO interactions in
226
the bulk phase and not from stabilization of a metastable polymorphic form. 12 ACS Paragon Plus Environment
Page 12 of 32
Page 13 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
227
228 229
Figure 4. Solubility of FRS, MFA, and TLB in EPO-solutions after 48 h equilibration at room
230
temperature.
231 232
To address potential pH effects on drug solubility, the pH was measured after 48 h for all
233
substances in EPO (0.5%, 2%, and 5%) (Table 5). For most compounds the pH dropped about
234
0.5 units. Maximum changes were observed in FRS suspensions where the pH dropped to pH
235
3.6 in 2% EPO and to pH 4.1 in 0.5% and 5% EPO. 13 ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 14 of 32
236 237
Table 5. pH of drug suspensions in EPO after 48 h at room temperature. Compound
pH in EPO 0.5% after 48 h
pH in EPO 2% after 48 h
pH in EPO 5% after 48 h
(Standard deviation, n=3)
(Standard deviation, n=3)
(Standard deviation, n=3)
BZF
4.5 (0.0)
4.6 (0.3)
4.7 (0.0)
FRS
4.1 (0.0)
3.6 (0.0)
4.1 (0.1)
IMC
4.8 (0.0)
4.4 (0.1)
4.9 (0.1)
MFA
5.6 (0.1)
5.2 (0.0)
5.4 (0.0)
PRX
5.4 (0.0)
5.5 (0.1)
5.6 (0.1)
TLB
5.2 (0.1)
5.4 (0.1)
5.6 (0.0)
WFN
5.4 (0.1)
5.4 (0.1)
5.7 (0.1)
238 239
As a trend, the pH was slightly higher in 5% EPO compared to the pH in 0.5% and 2% EPO.
240
The dimethylaminoethyl groups in EPO have a rather high pKa value (8.4)20 and thus
241
concentration-dependent interactions with the dissolving acidic drugs are likely to affect
242
equilibrium pH.
243 244
1
H NMR spectroscopy
245
1
H-NMR measurements were performed to evaluate the interactions between EPO and the
246
compounds in solution. Peaks originating from protons of aromatic ring systems (present in
247
all API molecules investigated) were observed between 7.00 and 8.25 ppm in D2O for PRX
248
and 6.75 to 8.00 ppm for WFN.
14 ACS Paragon Plus Environment
Page 15 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
249 250
Figure 5. Solution-state 1H-NMR spectra of WFN and PRX in presence of EPO and in D2O
251
alone.
252
The NMR signals of WFN and PRX in D2O were very sharp (see Fig. 5), indicating that API-
253
molecules were dispersed in D2O without substantial aggregation. This was also observed for
254
the other compounds (spectra not shown). All drugs had in common that API-related signals
255
displayed changes in line-width and/or chemical shift in presence of EPO as shown for two
256
examples, WFN and PRX, in Figure 5. Peaks derived from compounds could be still clearly
257
observed although the peaks’ shapes were comparatively much broader.
258
1
259
without 0.5% EPO and results are displayed in Table 6.
H-NMR was further used to measure the diffusion coefficient of the APIs in D2O with and
260
261
Table 6. Diffusion coefficient of APIs in D2O with and without EPO. Compound BZF
Diffusion coefficient in D2O × 1010 [m2/s] 4.65
Diffusion coefficient in EPO 0.5% × 1010 [m2/s] 0.56
FRS
4.73
0.36
IMC
5.25
0.34
MFA
5.50
0.34
PRX
5.43
0.63
15 ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
TLB
5.40
1.32
WFN
7.00
0.48
EPO
0.38
-
262
263
As expected, the much larger polymer EPO showed a lower diffusion coefficient
264
(10 to 15-fold) than the APIs alone and therefore moves slower. The EPO diffusion
265
coefficient was practically unaffected by the different drugs (in the range 5.3·10-11 to 3.7·10-11
266
m2/s). By contrast, the diffusion coefficient of the APIs decreased substantially in the
267
presence of EPO down to or even slightly below the diffusion coefficient of EPO.
268 269
Discussion
270
It is a reasonable assumption that the ionic interaction between the deprotonated drug and
271
protonated amino alkyl group of EPO provides important contribution to the whole
272
interaction. As an example of such a likely molecular association of drug and excipient, the
273
potential EPO-MFA interaction is depicted in Figure 6.
274 275
Figure 6. Graphical representation of the interaction of ionized molecules and ionized EPO
276
using mefenamic acid as model (light gray).
16 ACS Paragon Plus Environment
Page 16 of 32
Page 17 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
277
MFA was selected as an example since its interaction with EPO has been investigated before
278
in studies addressing supersaturation.13 Figure 6 shows that apart from association of the ionic
279
groups, additional interactions e.g. between side chain methyl groups and the aromatic ring,
280
are likely in case of MFA. Especially, the amino group may increase the polarization of the
281
methyl C-H group and thereby favor interaction with an aromatic ring. Similarly hydrophobic
282
interactions between the dangling EPO side chains and aromatic drug moieties may further
283
strengthen overall association. Higashi et al. studied the interaction mechanism of MFA with
284
EPO by high resolution magic-angle spinning NMR and also divided the molecular
285
interactions into ionic and hydrophobic interactions.13 They also identified peaks that indicate
286
interactions between the amino alkyl group of EPO and the aromatic systems of MFA.13 In
287
line with these results, Figure 6 shows that interactions with at least three spatial contacts
288
could be viewed as a kind of molecular recognition in the case of MFA and EPO. Thus, EPO
289
might form a kind of a polymeric pocket for MFA and additional interactions are conceivable
290
that further shield MFA from the aqueous environment. Based on the example of MFA, we
291
assume that such specific interaction motifs may also occur with other acidic drugs. In
292
summary, these motifs are the interaction of acidic and positively charged amino alkyl group,
293
the interaction of methyl amino group and aromatic rings, and additional hydrophobic
294
interactions. Even though all tested compounds can in principle show such interaction motifs,
295
the molecular structures are quite diverse and these structural differences are very likely to
296
influence the specific strength of molecular association between polymer and compound.
297
MFA has a carboxylic acid group whereas other compounds, like PRX, TLB, and WFN, have
298
alternative acidic groups (enolate or sulfonamide). When looking at Table 6, it is quite
299
remarkable that the diffusion coefficient of TLB decreases the least in presence of polymer.
300
Comparing all the structures, TLB is the only compound that has only one aromatic ring. All
301
other compounds have at least two aromatic rings. Thus the number of aromatic rings could
302
be important for the polymer-drug interaction, for example in case of MFA, the interaction of 17 ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
303
the methyl amino group and of the aromatic ring. Such interaction motifs also require that an
304
aromatic ring is spatially arranged close to the amino alkyl side chain of EPO. Therefore
305
molecular flexibility and hence rotatable bonds adjacent to aromatic systems are also very
306
likely associated with a strong polymer-drug interaction and in turn also with a good SE. FRS
307
and WFN showed excellent SE and these drugs are also flexible regarding their spatial
308
arrangement of their aromatic groups.
309 310
Theoretically, a certain initial conformation of the polymer might be optimal for drug
311
solubilization. However, at the same time, the presence of API molecules may also influence
312
conformation of the polymer. It is therefore expected that due to these complex molecular
313
interactions, no simple relationship can be established between the polymer concentration and
314
drug solubility. Concentration dependent solubility data were indeed in agreement with this
315
view since there was no general solubilization pattern evidenced for the different compounds
316
(Figures 3-4). Nonetheless, it is remarkable that most acidic drugs show a solubility maximum
317
at 2% EPO. Drug solubility was measured in a broad concentration range of EPO and
318
solubility could be affected by both the initial conformational structure of the polymer in
319
solution and by the conformation induced by its interaction with the drug.
320
For most compounds we observed a maximum of SE within the range of polymer
321
concentration investigated. For those which do not show this maximum the curvature of the
322
solubility increase proposed a maximum (or plateau) outside the range of polymer
323
concentration investigated. Eventually, these compounds will show beyond the tested range
324
also a maximum for SE at a certain polymer concentration. These observed maxima can be
325
explained by steric hindrance of the interactions between EPO and the APIs occurring at high
326
polymer loads. In addition conformational changes of the polymer at high concentration may
327
lead to limited accessibility of the polymeric cavities that enable strong drug association.
328 18 ACS Paragon Plus Environment
Page 18 of 32
Page 19 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
329
The molecular interactions discussed and exemplarily shown in Figure 6 were in agreement
330
with our 1H-NMR results. Notable was for example that all drugs revealed changes in the
331
aromatic regions, where a change in line-width and/or chemical shift for peaks originated
332
from protons of aromatic rings in presence of EPO. These results are in line with former
333
results, where similar line broadening was observed for MFA due to strong interaction with
334
EPO.13 Besides spectral information, drug diffusion coefficients of the compounds in presence
335
and absence of EPO were used to monitor the strength of the API polymer interactions in
336
solution.
337 338
Figure 7. SE in presence of polymer (0.5% (w/w)) plotted against the rDiffAPI defined as the
339
diffusion coefficient of drug with polymer divided by the value of pure drug in D2O.
340
A relative diffusion coefficient (rDiffAPI) was considered that holds for the observed value of
341
drug in the presence of polymer normalized by the diffusion coefficient of drug alone (in
342
D2O). When rDiffAPI is plotted against the relative SE of the drug (drug solubility in polymer
343
solution normalized by the pure aqueous solubility) there appears to be a non-linear
344
relationship. A Spearman rank correlation provided a coefficient of rSpearman = -0.83 that 19 ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
345
supported the view of a significant relationship (p= 0.04). Thus, a decrease of diffusion
346
coefficient ratio correlates well with an observed excipient SE (Figure 7). It is expected that
347
APIs diffusion will be increasingly reduced by stronger interaction with EPO and therefore, a
348
relative diffusion coefficient might be used as marker for the strength of drug-excipient
349
interaction in the bulk phase. The approach seems promising because no additional effects of
350
the drug solid state were evidenced in presence of polymer. Based on the identified
351
correlation, it might be in the future possible to formulate an empirical power law that
352
describes SE as a function of rDiffAPI but this should be based on an even larger dataset than
353
presented in the current study.
354
355
The non-linear nature of the relationship is likely due to a complex solid-liquid equilibrium
356
where drug in the bulk phase can be either interacting or non-interacting with polymer. It is
357
possible that presence of drug may induce conformational change of the polymer, thereby
358
influencing its binding. On top of such multiphase consideration, one may also have to
359
account for fractal physics of drug dissolution and diffusion.21-23 Such further theoretical
360
research is beyond the scope of the present article. The observed empirical correlation has in
361
any case a great practical relevance because it suggests how the strength of the molecular
362
interaction, expressed by rDiffAPI, may translate into SE. It is here interesting that a moderate
363
change in the strength of molecular interaction can exert a huge effect on solubilization.
364
365
Further possible correlations were studied between characteristics of the compounds (used for
366
general solubility prediction24) like logP, melting point, or pKa of the APIs and the solubility
367
enhancement by EPO (data shown in supplementary data). As a result, the present dataset did
368
not point to a comparatively simple relationship of such a molecular parameter with SE, 20 ACS Paragon Plus Environment
Page 20 of 32
Page 21 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
369
which was probably due to the complex nature of ionic and relevant hydrophobic interactions
370
of drug and polymer.
371
372
Conclusion
373
In former studies it was shown that EPO is a very potent polymer for stabilizing amorphous
374
acidic compounds, which can increase oral bioavailability.12, 13 We studied the influence of
375
EPO in solution on seven crystalline acidic drugs and could show that the observed huge SE
376
was enabled by specific molecular interactions of drug and polymer. Thus, EPO seems to be a
377
very well suitable polymer to formulate anionic drugs in both solid dispersions and in less
378
complex formulations such as solutions or suspensions. The exceptional drug solubilization
379
by EPO may even replace solid dispersions in many cases. This is attractive because simple
380
formulations that are easy to produce and stable upon storage are clearly preferred particularly
381
for early stage development. An important finding was also that a ratio of diffusion
382
coefficients of an API measured by NMR in presence and absence of EPO correlated well
383
with the obtained excipient solubility enhancement. The findings suggested that small
384
changes in the strength of molecular interaction between APIs and EPO may substantially
385
affect drug solubility in the presence of EPO. Based on the comparison of the acidic drugs, a
386
better molecular understanding was achieved for the association of drug and polymer to target
387
maximum solubility. Such findings of molecular pharmaceutics are of practical relevance and
388
it is particularly the early development phase that benefits from such knowledge to formulate
389
poorly soluble drugs, while coping with challenges of limited compound availability and
390
stretched timelines. The results are also interesting for oral solid dosage forms in the later
391
stage of pharmaceutical development where EPO could be used as well for SE.
392
21 ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
393
References
394
1.
395
approaches to estimate solubility and permeability in drug discovery and development settings. Adv.
396
Drug Deliv. Rev. 1997, 23, (1-3), 3-25.
397
2.
398
therapy: Rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev.
399
2001, 47, (1), 3-19.
400
3.
401
Improvement in solubility and dissolution rate of flavonoids by complexation with beta-cyclodextrin.
402
J. Pharm. Biomed. Anal. 2004, 35, (2), 379-387.
403
4.
404
Nat. Rev. Drug Discov. 2004, 3, (12), 1023-1035.
405
5.
406
Am. J. Drug Deliv. 2004, 2, (4), 261-275.
407
6.
408
water soluble drugs. Adv. Drug Deliv. Rev. 1997, 25, (1), 103-128.
409
7.
410
Absorption: Physical and Biopharmaceutical Aspects. Pharm. Res. 1995, 12, (11), 1561-1572.
411
8.
412
subsequent problems, and recent breakthroughs. J. Pharm. Sci. 1999, 88, (10), 1058-1066.
413
9.
414
inhibitors to improve the absorption of poorly water-soluble drugs: A mechanistic basis for utility. J.
415
Drug Target. 2010, 18, (10), 704-731.
416
10.
417
bioavailability of poor water soluble drugs. Drug Discov. Today 2007, 12, (23–24), 1068-1075.
418
11.
419
combinations of (meth)acrylate copolymers. Pharm. Dev. Technol. 2008, 13, (5), 413-423.
Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational
Müller, R. H.; Jacobs, C.; Kayser, O. Nanosuspensions as particulate drug formulations in
Tommasini, S.; Raneri, D.; Ficarra, R.; Calabro, M. L.; Stancanelli, R.; Ficarra, P.
Davis, M. E.; Brewster, M. E. Cyclodextrin-based pharmaceutics: Past, present and future.
Loftsson, T.; Brewster, M.; Másson, M. Role of cyclodextrins in improving oral drug delivery.
Humberstone, A. J.; Charman, W. N. Lipid-based vehicles for the oral delivery of poorly
Constantinides, P. Lipid Microemulsions for Improving Drug Dissolution and Oral
Serajuddin, A. T. M. Solid dispersion of poorly water-soluble drugs: Early promises,
Warren, D. B.; Benameur, H.; Porter, C. J. H.; Pouton, C. W. Using polymeric precipitation
Vasconcelos, T.; Sarmento, B.; Costa, P. Solid dispersions as strategy to improve oral
Gallardo, D.; Skalsky, B.; Kleinebudde, P. Controlled release solid dosage forms using
22 ACS Paragon Plus Environment
Page 22 of 32
Page 23 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
420
12.
Kojima, T.; Higashi, K.; Suzuki, T.; Tomono, K.; Moribe, K.; Yamamoto, K. Stabilization of a
421
Supersaturated Solution of Mefenamic Acid from a Solid Dispersion with EUDRAGIT® EPO.
422
Pharm. Res. 2012, 29, (10), 2777-2791.
423
13.
424
Ramamoorthy, A. Insights into Atomic-Level Interaction between Mefenamic Acid and Eudragit EPO
425
in a Supersaturated Solution by High-Resolution Magic-Angle Spinning NMR Spectroscopy. Mol.
426
Pharm. 2014, 11, (1), 351-357.
427
14.
428
dispersion: A simple and potent method to solve the problems of curcumin. Eur. J. Pharm. Biopharm.
429
2015, 94, 322-332.
430
15.
431
indomethacin with Eudragit® E during dissolution. Eur. J. Pharm. Biopharm. 2013, 85, (3, Part B),
432
1259-1265.
433
16.
434
P. A. Glass solution formation in water - In situ amorphization of naproxen and ibuprofen with
435
Eudragit® E PO. J. Drug Deliv. Sci. Tec. 2016, 34, 32-40.
436
17.
437
screening (SORESOS) in early drug development. Pharm. Res. 2007, 24, (5), 888-898.
438
18.
439
dispensing. Powder Technol. 2011, 209, (1-3), 152-157.
440
19.
441
Experiment Incorporating Bipolar-Gradient Pulses. J. Magn. Reson. Ser. A 1995, 115, (2), 260-264.
442
20.
ChemAxon http://www.chemicalize.org/ (19.11.2015).
443
21.
Farin, D.; Avnir, D. Use of fractal geometry to determine effects of surface morphology on
444
drug dissolution. J. Pharm. Sci. 1992, 81, (1), 54-57.
445
22.
446
Delivery nano Systems (chi-aDDnSs): Physicochemical and structural characterization, stability and
447
drug release studies. Int. J. Pharm. 2013, 450, (1–2), 1-10.
Higashi, K.; Yamamoto, K.; Pandey, M. K.; Mroue, K. H.; Moribe, K.; Yamamoto, K.;
Li, J. L.; Lee, I. W.; Shin, G. H.; Chen, X. G.; Park, H. J. Curcumin-Eudragit (R) E PO solid
Priemel, P. A.; Laitinen, R.; Grohganz, H.; Rades, T.; Strachan, C. J. In situ amorphisation of
Doreth, M.; Löbmann, K.; Grohganz, H.; Holm, R.; Lopez de Diego, H.; Rades, T.; Priemel,
Wyttenbach, N.; Alsenz, J.; Grassmann, O. Miniaturized assay for solubility and residual solid
Alsenz, J. Powder Picking: An inexpensive, manual, medium-throughput method for powder
Wu, D. H.; Chen, A. D.; Johnson, C. S. An Improved Diffusion-Ordered Spectroscopy
Pippa, N.; Merkouraki, M.; Pispas, S.; Demetzos, C. DPPC:MPOx chimeric advanced Drug
23 ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
448
23.
Niederquell, A.; Kuentz, M. Biorelevant dissolution of poorly soluble weak acids studied by
449
UV imaging reveals ranges of fractal-like kinetics. Int. J. Pharm. 2014, 463, (1), 38-49.
450
24.
451
(GSE). J. Chem. Inf.Comp. Sci. 2001, 41, (2), 354-357.
Ran, Y.; Yalkowsky, S. H. Prediction of Drug Solubility by the General Solubility Equation
452
24 ACS Paragon Plus Environment
Page 24 of 32
Page 25 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
Figure 1. Molecular structure of Eudragit® EPO. EPO was more recently used to 37x29mm (600 x 600 DPI)
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Figure 2. Chemical structure of model drugs. Chemical structures of all mod 58x22mm (600 x 600 DPI)
ACS Paragon Plus Environment
Page 26 of 32
Page 27 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
Figure 3. Solubility of BZF, IMC, PRX, and WFN in EPO-solutions after 48 h equilibration at room temperature. BZF, IMC, PRX and WFN (Figure 118x87mm (600 x 600 DPI)
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Figure 4. Solubility of FRS, MFA, and TLB in EPO-solutions after 48 h equilibration at room temperature To address potential pH effect 163x333mm (600 x 600 DPI)
ACS Paragon Plus Environment
Page 28 of 32
Page 29 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
Figure 5. Solution-state 1H-NMR spectra of WFN and PRX in presence of EPO and in D2O alone. The NMR signals of WFN and PRX 65x52mm (600 x 600 DPI)
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Figure 6. Graphical representation of the interaction of ionized molecules and ionized EPO using mefenamic acid as model (light gray). MFA was selected as an example 73x66mm (600 x 600 DPI)
ACS Paragon Plus Environment
Page 30 of 32
Page 31 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
Figure 7. SE in presence of polymer (0.5% (w/w)) plotted against the rDiffAPI defined as the diffusion coefficient of drug with polymer divided by the value of pure drug in D2O. A relative diffusion coefficie 92x57mm (600 x 600 DPI)
ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Graphical abstract 32x11mm (600 x 600 DPI)
ACS Paragon Plus Environment
Page 32 of 32